Repligen Co. (NASDAQ:RGEN) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its holdings in Repligen Co. (NASDAQ:RGEN) by 77.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,535 shares of the biotechnology company’s stock after selling 47,504 shares during the quarter. BNP Paribas Financial Markets’ holdings in Repligen were worth $2,434,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. Teacher Retirement System of Texas boosted its holdings in Repligen by 2.5% in the third quarter. Teacher Retirement System of Texas now owns 4,098 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 101 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Repligen by 3.2% in the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock valued at $509,000 after acquiring an additional 100 shares during the period. WealthPlan Investment Management LLC acquired a new stake in shares of Repligen in the third quarter valued at approximately $210,000. Nisa Investment Advisors LLC boosted its holdings in shares of Repligen by 67.6% in the third quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 215 shares during the period. Finally, California Public Employees Retirement System boosted its holdings in shares of Repligen by 1.1% in the third quarter. California Public Employees Retirement System now owns 83,567 shares of the biotechnology company’s stock valued at $13,288,000 after acquiring an additional 910 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,296 shares of company stock worth $7,550,643. 1.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RGEN shares. KeyCorp increased their price objective on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. decreased their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, Stifel Nicolaus increased their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $197.75.

Repligen Price Performance

Repligen stock opened at $158.78 on Friday. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The business has a 50 day simple moving average of $174.10 and a 200-day simple moving average of $177.17. The stock has a market capitalization of $8.87 billion, a PE ratio of 635.15, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The business had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company’s revenue was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS. Equities analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.